摘要
目的探讨抑郁症患者BDNF Val66Met基因多态性与抗抑郁药疗效的关系。方法计算机检索数据库时间从2000年1月至2017年6月发表的关于BDNF Val66Met基因多态性与抗抑郁药疗效相关研究的国内外文献,采用Stata11软件进行Meta分析。结果共纳入20篇文献,包括3225例抑郁症患者。Meta分析显示,在抑郁症患者隐形模型中,MM基因型对抗抑郁药物的治疗反应较好P<0.05;亚组分析结果表明:在不同种族中,抑郁症患者BDNF Val66Met基因多态性与抗抑郁药疗效无统计学意义;在抗抑郁药SSRIs中,共显性模型VM基因型、显性模型VM+MM基因型对抗抑郁药物的治疗反应较好P<0.05;在给药时间>6周中,抑郁症患者M等位基因、隐性模型MM基因型对抗抑郁药物的治疗反应较好P<0.05。结论抗抑郁药SSRIs、给药时间>6周中,抑郁症患者BDNF Val66Met基因多态性与抗抑郁药疗效有相关性,该结果可对抗抑郁药个体化用药提供参考。
Objective To evaluate the association between BDNF Val66 Met polymorphism and antidepressant efficacy in depression patients. Methods Databases including Pub Med,EMbase,MEDLINE,CNKI,VIP,and Wan Fang Data were searched to collect studies on relationship between the BDNF Val66 Met polymorphism association and antidepressant efficacy in depression patients from January 2000 to June 2017. Then,meta-analysis was performed using Stata14. 0 software. Results Twenty articles were included in our research involving 3325 patients. The results of meta-analysis showed that the MM genotype in BDNF Val66 Met gene polymorphism responded better to antidepressant drugs in the recessive genetic model P 〈 0. 05. Subgroup analysis showed： 1. No association was found in the Asian and European; 2. In antidepressant SSRIs,the dominant genetic model and co-dominant genetic model VM and VM ＋ MM genotype responded better to antidepressants P 〈 0. 05; 3. In the group with treatment period≥6 weeks,the M allele and recessive genetic model MM genotype responded better to antidepressants P 〈 0. 05. Conclusion In the Antidepressants SSRIs and administration time 〉 6 weeks,BDNF Val66 Met gene polymorphism were correlated with antidepressant efficacy,the results could provide a reference to antidepressant individualized medication.
出处
《牡丹江医学院学报》
2018年第3期21-26,共6页
Journal of Mudanjiang Medical University
基金
安徽省自然科学基金面上项目(1308085MH126)
